China Heparin Industry Report, 2012-2014 Dec. 2012 STUDY GOAL AND OBJECTIVES METHODOLOGY This report provides the industry executives with strategically significant Both primary and secondary research methodologies were used competitor information, analysis, insight and projection on the in preparing this study. Initially, a comprehensive and exhaustive competitive pattern and key companies in the industry, crucial to the search of the literature on this industry was conducted. These development and implementation of effective business, marketing and sources included related books and journals, trade literature, R&D programs. marketing literature, other product/promotional literature, annual reports, security analyst reports, and other publications. REPORT OBJECTIVES Subsequently, telephone interviews or email correspondence To establish a comprehensive, factual, annually updated and cost- was conducted with marketing executives etc. Other sources effective information base on market size, competition patterns, included related magazines, academics, and consulting market segments, goals and strategies of the leading players in the companies. market, reviews and forecasts. To assist potential market entrants in evaluating prospective acquisition and joint venture candidates. To complement the organizations’ internal competitor information INFORMATION SOURCES The primary information sources include China Customs, and China Pharmaceutical Industry Association etc. gathering efforts with strategic analysis, data interpretation and insight. To suggest for concerned investors in line with the current development of this industry as well as the development tendency. To help company to succeed in a competitive market, and Copyright 2012 ResearchInChina understand the size and growth rate of any opportunity. Room 502, Block 3, Tower C, Changyuan Tiandi Building, No. 18, Suzhou Street, Haidian District, Beijing, China 100080 Phone: +86 10 82600828 ● Fax: +86 10 82601570 ● www.researchinchina.com ● report@researchinchina.com Abstract China, abundant in heparin raw materials, has become one of the 3.8% and 2.1% year-on-year respectively in Jan.-May, 2012, due to world’s largest heparin API producers and exporters, owning to the the improved quality of exported products as well as the low cardinal quality of heparin API having won international recognition gradually. number of exported prices in the preceding year. Due to the euro debt crisis, the global market suffered a deep recession. Coupled that the heparin export standard has lifted, China’s export volume of heparin API was no more than 105.2 tons in 2011, Export Volume and Export Value Change of China Top 10 Heparin and Heparinate Exporters, Jan.-May, 2012 approximating 14.6 trillion units (measured by 140IU/mg), with the proportion of around 45.9% in the global demand during the same period. Leading heparin API suppliers worldwide include Shenzhen Hepalink Pharmaceutical, Changzhou Qianhong Bio-Pharma, Yantai Dongcheng Biochemicals and Nanjing King-Friend Biochemical Pharmaceutical, which have ranked top 4 industrial players by export for several years in a row, with the combined export value making up more than 70% of China’s total export value of heparin. There is no distinct change in terms of the export pattern. However, the export prices of China’s top 10 heparin exporters witnessed a downward mobility in 2011-2012H1. Nevertheless, it was not the same case for Dongying Tiandong Pharmaceutical and Jiangsu Medicine Health Care Article Imp. & Exp. (Group), whose export prices increased by Copyright 2012ResearchInChina Room 502, Block 3, Tower C, Changyuan Tiandi Building, No. 18, Suzhou Street, Haidian District, Beijing, China 100080 Phone: +86 10 82600828 ● Fax: +86 10 82601570 ● www.researchinchina.com ● report@researchinchina.com Meanwhile, Chinese heparin API flagship enterprises including Shenzhen Hepalink Pharmaceutical, Changzhou Qianhong BioPharma, Yantai Dongcheng Biochemicals, Hebei Changshan Biochemical Pharmaceutical and Nanjing King-Friend Biochemical Pharmaceutical are projected to expand their capacities and improve the heparin industry chains. Among these tycoons, the first four ones have made IPO, while Nanjing King-Friend Biochemical Pharmaceutical is also preparing for IPO by accepting tutoring. According to public information issued by related enterprises, the heparin API capacity of However, with the improvement of R&D and technological strength, the competitiveness of made-in-China low molecular weight heparin preparation market is increasingly enhancing. A case in point is Hebei Changshan Biochemical Pharmaceutical Co., Ltd, the capacity of low molecular weight heparin calcium injection of which soared from 4 million pcs to 10 million pcs in 2011, with the sales increased by 68.4% year-on-year to RMB86.93 million, compared to the sales of RMB117 million in 2012H1, a year-on-year rise of 237.6%. China will increase by more than 18 trillion units by 2014, with the total capacity expected to exceed 30 trillion units, making up over 70% of the global demand. Although China is a large country with rich heparin API, the downstream production of general heparin preparation and low molecular weight heparin preparation is still at the initial stage. In the high-end low molecular weight heparin preparation market, especially, joint ventures and foreign brands including Sanofi-Aventis, Pfizer and GSK have eroded into the Chinese market. According to China Pharmaceutical Industry Association, imported low molecular weight heparin calcium accounted for more than 60% of the total procurement of such products of representative hospitals in 22 Chinese cities in 2011. Copyright 2012ResearchInChina Room 502, Block 3, Tower C, Changyuan Tiandi Building, No. 18, Suzhou Street, Haidian District, Beijing, China 100080 Phone: +86 10 82600828 ● Fax: +86 10 82601570 ● www.researchinchina.com ● report@researchinchina.com Table of contents 1. Profile of Heparin Industry 1.1 Definition & Classification 1.2 Industry Chain 2. Operating Environment of Chinese Heparin Industry 2.1 Entry Barriers 2.1.1 Policies 2.1.2 Technical Requirements 2.1.3 Capital Barrier 2.2 Supply and Demand in Global Market 2.3 Competition in Global Market 2.4 Global Market Forecast 3. Development of Heparin API Industry in China 3.1 Market Status Quo 3.2 Market Supply and Demand 3.3 Competitive Landscape 3.4 Import & Export 3.4.1 Export 3.4.2 Import 3.5 Development Outlook & Forecast 4. Development of Heparin Preparation Industry in China 4.1 Market Size 4.2 Competition Pattern 4.3 Market Segments 4.3.1 Low Molecular Weight Heparin Preparation 4.3.2 General Heparin Preparation 4.4 Development Outlook & Forecast 5. Key Chinese Heparin Manufacturers 5.1 Shenzhen Hepalink Pharmaceutical Co., Ltd 5.1.1 Profile 5.1.2 Operation 5.1.3 Revenue Structure 5.1.4 Gross Margin 5.1.5 R&D and Investment 5.1.6 Clients and Suppliers 5.1.7 Prospects 5.2 Changzhou Qianhong Bio-Pharma Co., Ltd 5.2.1 Profile 5.2.2 Operation 5.2.3 Revenue Structure 5.2.4 Gross Margin 5.2.5 R&D and Investment 5.2.6 Clients and Suppliers 5.2.7 Heparin Business 5.2.8 Prospects 5.3 Yantai Dongcheng Biochemicals Co., Ltd 5.3.1 Profile 5.3.2 Operation 5.3.3 Revenue Structure 5.3.4 Gross Margin 5.3.5 R&D and Investment 5.3.6 Clients and Suppliers 5.3.7 Heparin Business 5.3.8 Prospects 5.4 Hebei Changshan Biochemical Pharmaceutical Co., Ltd 5.4.1 Profile 5.4.2 Operation 5.4.3 Revenue Structure 5.4.4 Gross Margin 5.4.5 R&D and Investment 5.4.6 Clients and Suppliers 5.4.7 Prospects 5.5 Tianjin Chase Sun Pharmaceutical Co., Ltd 5.5.1 Profile 5.5.2 Operation 5.5.3 Revenue Structure 5.5.4 Gross Margin 5.5.5 R&D and Investment 5.5.6 Clients and Suppliers 5.5.7 Heparin Business 5.5.8 Prospects 5.6 Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd 5.6.1 Profile 5.6.2 Operation and Prospects 5.7 Wanbang Biopharmaceuticals 5.7.1 Profile 5.7.2 Operation and Prospects Room 502, Block 3, Tower C, Changyuan Tiandi Building, No. 18, Suzhou Street, Haidian District, Beijing, China 100080 Phone: +86 10 82600828 ● Fax: +86 10 82601570 ● www.researchinchina.com ● report@researchinchina.com Selected Charts • • • • • • • • • • • • • • • • • • • • • • • • • • Application of Heparin Preparations Heparin Industry Chain Difference between Heparin Sodium API and Heparin Standardized Requirements Heparin Preparation Market Scale and YoY Growth Worldwide, 2006-2011 Performance: Low Molecular Weight Heparin Preparation vs. General Heparin Preparation Global Heparin Preparation Distribution by Region, 2011 Heparin API Demand and YoY Growth Worldwide, 2007-2011 Sales of Enoxaparin Worldwide by Product, 2010-2012 Regulatory Exclusivity of Lovenox, as of late 2011 Global Heparin Preparation Market Scale, 2011-2014E Global Heparin API Demand, 2011-2014E Gross Margin of Major Heparin API Manufacturers in China, 2008-2012 Capacity of Crude Heparin in China, 2009-2011 Average Export Price of Heparin and Heparinate, 2008-2012 Capacity of Major Heparin API Manufacturers in China, as of June 2012 Export Volume and Export Value of Heparin and Heparinate in China, 2008-2012 Export Price of Heparin and Heparinate in China, 2008-2012 Top 10 Export Destinations of Heparin and Heparinate in China by Value, 2011-2012 Top 10 Heparin and Heparinate Enterprises in China by Export Value, 2011 Export Volume and Export Value of Heparin and Heparinate in China, Jan.-May, 2012 Import Volume, Import Value and Unite Price of Heparin and Heparinate in China, 2008-2011 Planned / Ongoing Heparin Sodium API Projects in China, as of June 2012 Heparin Preparation Market Scale and YoY Growth of China, 2007-2011 Market Share of Heparin Preparation Products in China, 2011 Main Manufacturers of Heparin Sodium Injection Solution and Heparin Calcium Injection Solution in China Manufacturers of Low-molecular Heparin Sodium Preparations and Low-molecular Heparin Calcium Preparations Room 502, Block 3, Tower C, Changyuan Tiandi Building, No. 18, Suzhou Street, Haidian District, Beijing, China 100080 Phone: +86 10 82600828 ● Fax: +86 10 82601570 ● www.researchinchina.com ● report@researchinchina.com Selected Charts • • • • • • • • • • • • • • • • • • • • • • • • • • China Low Molecular Weight Heparin Preparation Market Scale, 2009-2011 Purchase Value of Low Molecular Weight Heparin Calcium of Chinese Representative Hospitals, 2010-2011 Low Molecular Weight Heparin Preparation Imported Value of Representative Hospitals in 22 Chinese Cities, 2010-2011 Competition Pattern of China Low Molecular Weight Heparin Calcium Market, 2009 Competition Pattern of China Low Molecular Weight Heparin Sodium Market, 2009 China Heparin Preparation Market Scale and YoY Growth, 2011-2014 Assets and Net Income of Holding Subsidiaries under Hepalink, 2012H1 Revenue and Profit of Hepalink, 2008-2012 Revenue of Hepalink by Product, 2008-2012 Revenue of Hepalink by Region, 2008-2012 Gross Margin of Hepalink by Product, 2008-2012 R&D Investment and Proportion in Revenue of Hepalink, 2009-2011 Revenue of Hepalink from the Top 5 Clients and Proportion, 2008-2012 Revenue and Operating Income of Hepalink, 2011-2014E Assets, Revenue and Net Income of Subsidiaries under Qianhong Bio-Pharma, 2012H1 Revenue and Profit of Qianhong Bio-Pharma, 2008-2012 Revenue of Qianhong Bio-Pharma by Product, 2008-2012 Revenue of Qianhong Bio-Pharma by Region, 2008-2012 Gross Margin of Qianhong Bio-Pharma by Product, 2008-2012 R&D Investment and Proportion in Revenue of Qianhong Bio-Pharma, 2009-2011 Scheduling of Planned/Ongoing Projects of Qianhong Bio-Pharma, as of June 2012 Top 5 Clients, Revenue Contribution and Proportion of Qianhong Bio-Pharma, 2011 Purchase Value of Qianhong Bio-Pharma’s Top 5 Suppliers and Revenue Contribution of Qianhong Bio-Pharma’s Top 5 Clients, 2009-2012 Revenue and Gross Margin from Heparin Business of Qianhong Bio-Pharma, 2008-2012 Revenue and Operating Income of Qianhong Bio-Pharma, 2011-2014 Assets, Revenue and Net Income of Subsidiaries under Dongcheng Biochemicals, 2012H1 Room 502, Block 3, Tower C, Changyuan Tiandi Building, No. 18, Suzhou Street, Haidian District, Beijing, China 100080 Phone: +86 10 82600828 ● Fax: +86 10 82601570 ● www.researchinchina.com ● report@researchinchina.com Selected Charts • • • • • • • • • • • • • • • • • • • • • • • • • • Revenue and Profit of Dongcheng Biochemicals, 2008-2012 Revenue of Dongcheng Biochemicals by Product, 2008-2012 Revenue of Dongcheng Biochemicals by Region, 2008-2012 Gross Margin of Dongcheng Biochemicals by Product, 2008-2012 R&D Investment and Proportion in Revenue of Dongcheng Biochemicals, 2008-2012 Revenue and Gross Margin from Heparin Sodium API Business of Dongcheng Biochemicals, 2008-2012 Heparin Sodium API Price of Dongcheng Biochemicals, 2009-2011 Revenue Contribution of Dongcheng Biochemicals’ Top 5 Heparin Sodium API Clients, 2009-2011 Scheduling of Heparin Sodium API Projects of Dongcheng Biochemicals, 2013-2015E Revenue and Profit of Dongcheng Biochemicals, 2011-2014E Revenue and Profit of Hebei Changshan Biochemical Pharmaceutical, 2008-2012 Revenue of Hebei Changshan Biochemical Pharmaceutical by Product, 2008-2012 Revenue of Hebei Changshan Biochemical Pharmaceutical by Region, 2008-2012 Gross Margin of Hebei Changshan Biochemical Pharmaceutical by Product, 2008-2012 R&D Investment and Proportion in Revenue of Hebei Changshan Biochemical Pharmaceutical, 2009-2011 Product Research Scheduling of Hebei Changshan Biochemical Pharmaceutical, as of late 2011 Name List, Revenue Contribution and Proportion of Top 5 Clients of Hebei Changshan Biochemical Pharmaceutical, 2011 Heparin Product Certificates Won by Hebei Changshan Biochemical Pharmaceutical Overseas, as of late 2011 Revenue and Profit of Hebei Changshan Biochemical Pharmaceutical, 2011-2014E Revenue and Profit of Tianjin Chase Sun Pharmaceutical, 2008-2012 Revenue of Tianjin Chase Sun Pharmaceutical by Product, 2008-2012 Revenue of Tianjin Chase Sun Pharmaceutical by Region, 2008-2012 Gross Margin of Tianjin Chase Sun Pharmaceutical by Product, 2008-2012 R&D Investment and Proportion in Revenue of Tianjin Chase Sun Pharmaceutical, 2009-2011 Name List, Revenue Contribution and Proportion of Top 5 Clients of Tianjin Chase Sun Pharmaceutical, 2011 Name Room List, Purchase Value and Proportion of Top 5 Suppliers of No. Tianjin Pharmaceutical, 2011 502, Block 3, Tower C, Changyuan Tiandi Building, 18, Chase SuzhouSun Street, Haidian District, Beijing, China 100080 Phone: +86 10 82600828 ● Fax: +86 10 82601570 ● www.researchinchina.com ● report@researchinchina.com Selected Charts • • • Revenue and Gross Margin from Heparin Business of Tianjin Chase Sun Pharmaceutical, 2008-2012 Revenue and Operating Income of Tianjin Chase Sun Pharmaceutical, 2011-2014 Assets and Net Income of Wanbang Biopharmaceuticals, 2008-2011 Room 502, Block 3, Tower C, Changyuan Tiandi Building, No. 18, Suzhou Street, Haidian District, Beijing, China 100080 Phone: +86 10 82600828 ● Fax: +86 10 82601570 ● www.researchinchina.com ● report@researchinchina.com How to Buy You can place your order in the following alternative ways: Choose type of format 1.Order online at www.researchinchina.com PDF (Single user license) …………..1,900 USD 2.Fax order sheet to us at fax number:+86 10 82601570 Hard copy 3. Email your order to: report@researchinchina.com ………………….……. 2,000 USD PDF (Enterprisewide license)…....... 3,000 USD 4. Phone us at +86 10 82600828/ 82601561 Party A: Name: Address: Contact Person: E-mail: ※ Reports will be dispatched immediately once full payment has been received. Tel Fax Payment may be made by wire transfer or Party B: Name: Address: Beijing Waterwood Technologies Co., Ltd (ResearchInChina) Room 502, Block 3, Tower C, Changyuan Tiandi Building, No. 18, Suzhou Street, Haidian District, Beijing, China 100080 Liao Yan Phone: 86-10-82600828 credit card via PayPal. Contact Person: E-mail: report@researchinchina.com Fax: 86-10-82601570 Bank details: Beneficial Name: Beijing Waterwood Technologies Co., Ltd Bank Name: Bank of Communications, Beijing Branch Bank Address: NO.1 jinxiyuan shijicheng,Landianchang,Haidian District,Beijing Bank Account No #: 110060668012015061217 Routing No # : 332906 Bank SWIFT Code: COMMCNSHBJG Title Format Cost Total Room 502, Block 3, Tower C, Changyuan Tiandi Building, No. 18, Suzhou Street, Haidian District, Beijing, China 100080 Phone: +86 10 82600828 ● Fax: +86 10 82601570 ● www.researchinchina.com ● report@researchinchina.com